Literature DB >> 24378789

Market watch: Are orphan drug companies the pick of the pharmaceutical industry?

Thomas Morel1, Cedric Popa2, Steven Simoens3.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24378789     DOI： 10.1038/nrd4205

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study.

Authors:  Dyfrig A Hughes; Jannine Poletti-Hughes
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

2.  Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.

Authors:  Tim A Kanters; Ans T van der Ploeg; Michelle E Kruijshaar; Dimitris Rizopoulos; W Ken Redekop; Maureen P M H Rutten-van Mӧlken; Leona Hakkaart-van Roijen
Journal:  Orphanet J Rare Dis       Date:  2017-12-13       Impact factor: 4.123

3.  Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law.

Authors:  Gail A Van Norman
Journal:  JACC Basic Transl Sci       Date:  2017-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.